Key Moments
ApoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease [AMA 43 sneak peek]
Peter Attia MDKey Moments
ASCVD risk factors explained: ApoB, LDL-C, Lp(a), insulin, and how they interact.
Key Insights
ApoB is a superior marker for cardiovascular risk compared to LDL-C, as it accounts for all atherogenic particles.
High Lp(a) is an inherited risk factor that increases throttle on cardiovascular disease progression.
Hyperinsulinemia, a precursor to Type 2 Diabetes, accelerates cardiovascular disease risk through various mechanisms.
Insulin resistance impacts ApoC3 expression, leading to increased triglycerides and ApoB levels.
Insulin can also directly contribute to endothelial dysfunction, facilitating particle entry into arterial walls.
The OGTT (Oral Glucose Tolerance Test) can reveal hyperinsulinemia before overt Type 2 Diabetes develops.
THE RACECAR ANALOGY FOR CARDIOVASCULAR RISK
Peter Attia introduces a racecar analogy to explain cardiovascular disease (ASCVD) risk. The lifespan is the journey, with the cliff representing death. The accelerator represents factors that speed up progression, while the brake represents factors that slow it down. Lp(a) acts as a baseline throttle, inherently present based on genetics. ApoB levels are influenced by both throttle inputs and braking mechanisms. Factors like hyperinsulinemia (associated with Type 2 Diabetes) press harder on the accelerator, speeding up the journey towards the cliff. Conversely, interventions that lower ApoB, like pharmacotherapy, are akin to applying the brakes forcefully.
APOB VERSUS LDLC: A SUPERIOR RISK MARKER
Attia clarifies the distinction between LDL-C (Low-Density Lipoprotein Cholesterol) and ApoB (Apolipoprotein B). LDL-C measures the cholesterol concentration within LDL particles, while ApoB measures the total number of apolipoprotein B-containing particles, which include LDL, VLDL, and Lp(a). Attia emphasizes that ApoB is a more accurate predictor of ASCVD risk because it counts the actual number of atherogenic particles, which is more critical than just the cholesterol content within them. While LDL-C can be a predictor, ApoB provides a more comprehensive picture of risk, particularly when addressing residual risk.
THE MECHANISMS OF HYPERINSULINEMIA AND ASCVD
Hyperinsulinemia, often a precursor to Type 2 Diabetes, is a significant contributor to ASCVD. One primary mechanism is its effect on ApoC3 expression. Insulin resistance upregulates ApoC3, which inhibits lipoprotein lipase (LPL). Reduced LPL activity leads to decreased triglyceride utilization, resulting in higher triglyceride levels. Triglycerides are carried by VLDL particles, which are atherogenic, and if they persist, can become even more harmful remnants. This process also leads to an increase in triglyceride-rich LDL particles, consequently raising ApoB levels.
ENDOTHELIAL DYSFUNCTION AND INSULIN
Beyond its impact on lipid metabolism, hyperinsulinemia also contributes to endothelial dysfunction. The endothelium, the inner lining of blood vessels, plays a crucial role in vascular health. When it's dysfunctional, ApoB particles can more easily penetrate the vessel wall and enter the sub-endothelial space, initiating the atherosclerotic process. While harder to clinically measure directly, studies on cultured endothelial cells show that elevated insulin levels can impair their function. This impairment facilitates the cascade of events leading to plaque formation and ASCVD.
LITTLE A (LP little A) AS A GENETIC THROTTLE
High Lipoprotein(a) (Lp(a)) is identified as a key inherited risk factor for ASCVD, acting like a 'maintenance throttle' on the racecar analogy. Unlike factors that can be modified through lifestyle or medication, Lp(a) levels are largely determined by genetics. Individuals born with higher Lp(a) inherently have a greater propensity for cardiovascular disease progression. While specific strategies to significantly lower Lp(a) are still evolving, its presence necessitates careful management of other modifiable risk factors to counteract its accelerating effect.
ASSESSING INSULIN RESISTANCE AND GLUCOSE TOLERANCE
While Type 2 Diabetes is a well-defined condition based on A1C levels, Attia highlights the importance of identifying hyperinsulinemia earlier. The Oral Glucose Tolerance Test (OGTT) serves as a crucial diagnostic tool for this. It assesses how the body handles a glucose load, specifically looking for elevated insulin levels that may occur even when fasting glucose or A1C appear normal. Detecting this 'pre-diabetic' state of disturbed insulin response is vital for proactive intervention to mitigate ASCVD risk.
Mentioned in This Episode
●Supplements
●Products
●Tools
●Concepts
●People Referenced
Common Questions
ApoB measures the total number of atherogenic particles, including LDL, VLDL, and Lp(a). LDL-C measures the cholesterol within LDL particles. While both are risk predictors, ApoB is generally preferred for its comprehensive particle count. Lp(a) is a distinct atherogenic particle with a significant genetic component.
Topics
Mentioned in this video
An enzyme crucial for breaking down triglycerides in the blood, whose activity is inhibited by ApoC3, leading to increased triglyceride levels.
High-density lipoprotein cholesterol, often referred to as 'good' cholesterol, its concentration can be affected by hyperinsulinemia.
A condition where the endothelium (inner lining of blood vessels) loses its normal function, acting as a key risk factor for ASCVD and linked to insulin resistance.
A hormone that plays a critical role in glucose metabolism and is discussed as a significant risk factor for cardiovascular disease, especially when levels are elevated (hyperinsulinemia).
A blood test that measures average blood sugar levels over the past 2-3 months, used to diagnose diabetes and monitor glycemic control.
A protein involved in the exchange of lipids between lipoproteins, suggested to play a role in the decrease of HDL cholesterol seen with hyperinsulinemia.
A diagnostic test used to assess how the body metabolizes glucose, useful for identifying insulin resistance or pre-diabetes when fasting glucose and A1C are normal.
Very-low-density lipoprotein, an atherogenic particle that carries triglycerides and cholesterol, discussed in relation to insulin resistance and ApoB.
Low-density lipoprotein cholesterol, a measure of cholesterol within LDL particles, discussed as a predictor of cardiovascular risk.
Apolipoprotein C3, a protein implicated in regulating triglyceride metabolism and influencing ApoB levels, with its expression upregulated in insulin resistance.
A guest who previously discussed cardiovascular disease risk factors, particularly Lp(a) and the concept of 10-year vs. lifetime risk.
Host of The Drive podcast and the discussion's primary expert on cardiovascular disease and metabolic health.
A researcher or physician previously featured on the podcast to discuss insulin and its role in metabolic health and cardiovascular disease.
A legendary Formula 1 driver, whose 1988 car is mentioned in relation to a t-shirt.
More from Peter Attia MD
View all 333 summaries
135 min381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more
9 minIs Industrial Processing the Real Problem With Seed Oils? | Layne Norton, Ph.D.
13 minCooking with Lard vs Seed Oils | Layne Norton, Ph.D.
146 min380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Get Started Free